China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHA: 600062)

Market Cap	22.67B
Revenue (ttm)	10.32B
Net Income (ttm)	1.35B
Shares Out	1.03B
EPS (ttm)	1.31
PE Ratio	16.83
Forward PE	12.90
Dividend	0.20 (0.90%)
Ex-Dividend Date	Nov 8, 2024

Volume	13,726,736
Open	21.59
Previous Close	21.65
Day's Range	21.59 - 22.26
52-Week Range	15.94 - 26.15
Beta	0.14
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 28, 2024

About China Resources Double-Crane Pharmaceutical Co.,Ltd.

China Resources Double-Crane Pharmaceutical Co.,Ltd. operates as a pharmaceutical company in the People’s Republic of China. The company offers pharmaceutical products for blood pressure, blood sugar, injection, lipid-lowering, pediatrics, nephrology, API, pharmaceutical, and other. The company was founded in 1939 and is headquartered in Beijing, the People’s Republic of China. China Resources Double-Crane Pharmaceutical Co.,Ltd. operates as a subsidiary of Beijing Pharmaceutical Group Co., Ltd.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1939
• Employees: 12,269
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600062

Financial Performance

In 2023, China Resources Double-Crane Pharmaceutical Co.,Ltd.'s revenue was 10.22 billion, an increase of 6.20% compared to the previous year's 9.63 billion. Earnings were 1.33 billion, an increase of 12.96%.